Health Canada has authorized Eli Lilly's Foundayo, a daily oral GLP-1 medication for weight loss, making it the first pill of its kind approved in Canada for weight management.
Foundayo is approved for adults with obesity and those who are overweight with at least one related medical condition such as high blood pressure or sleep apnea. The medication also treats Type 2 diabetes. Eli Lilly received Health Canada authorization on Nov. 13, and the company expects the pills to be available in pharmacies in January.
The active ingredient, orforglipron, is a non-peptide GLP-1 receptor agonist. Because it is a smaller molecule than the peptides semaglutide and tirzepatide used in injectable competitors, orforglipron can be taken orally and absorbed without being broken down by the digestive system, said Dr. Ehud Ur, an endocrinologist in Vancouver.
"It seems to be just as good as if not better" for weight loss as semaglutide and tirzepatide, Ur said.
Eli Lilly also manufactures the injectable drugs Mounjaro and Zepbound, which contain tirzepatide and act on two receptors associated with insulin production and hunger: GLP-1 and GIP. Competitor Novo Nordisk makes the injectables Ozempic and Wegovy, which contain semaglutide and act on GLP-1 receptors.
Rybelsus, another GLP-1 pill from Novo Nordisk, is already available in Canada but is approved only for Type 2 diabetes management, not weight loss.
The most common side effects of GLP-1 medications, both injectable and oral, include gastrointestinal issues such as nausea or vomiting.
Ur said whether he would prescribe Foundayo depends on the patient, partly because he is awaiting clinical trial results on whether orforglipron has a cardiovascular benefit like semaglutide and tirzepatide do.
Novo Nordisk's Wegovy pill, which uses semaglutide with an added ingredient called salcaprozate sodium to protect it from digestive breakdown, is still awaiting Health Canada approval. Both Foundayo and the Wegovy pill are already approved and available in the United States.